269 related articles for article (PubMed ID: 18405848)
1. Impact of non-profit organizations on drug discovery: opportunities, gaps, solutions.
Matter A; Keller TH
Drug Discov Today; 2008 Apr; 13(7-8):347-52. PubMed ID: 18405848
[TBL] [Abstract][Full Text] [Related]
2. Ask the experts.
Pecoul B; Pollastri M; McKerrow J; Bueno-Calderon JM
Future Med Chem; 2012 Jul; 4(11):1383-9. PubMed ID: 22857528
[TBL] [Abstract][Full Text] [Related]
3. World's first nonprofit drug company launched.
Cassels A
CMAJ; 2003 Sep; 169(6):590. PubMed ID: 12975232
[No Abstract] [Full Text] [Related]
4. Geron-Roslin alliance aims broadly at degenerative diseases.
Fox JL
Nat Biotechnol; 1999 Jun; 17(6):529-30. PubMed ID: 10385308
[No Abstract] [Full Text] [Related]
5. Links between non-profit foundations and companies pose potential conflicts of interest.
Limb M
BMJ; 2011 Apr; 342():d2490. PubMed ID: 21498467
[No Abstract] [Full Text] [Related]
6. Optimizing the discovery organization for innovation.
Sams-Dodd F
Drug Discov Today; 2005 Aug; 10(15):1049-56. PubMed ID: 16055021
[TBL] [Abstract][Full Text] [Related]
7. In search of sustainability: process R&D in light of current pharmaceutical industry challenges.
Federsel HJ
Drug Discov Today; 2006 Nov; 11(21-22):966-74. PubMed ID: 17055405
[TBL] [Abstract][Full Text] [Related]
8. An audience with... Victoria G. Hale.
Hale VG
Nat Rev Drug Discov; 2005 Nov; 4(11):878. PubMed ID: 16299916
[No Abstract] [Full Text] [Related]
9. New generation of non-profit initiatives tackles world's "neglected" diseases.
Mandelbaum-Schmid J
Bull World Health Organ; 2004 May; 82(5):395-6. PubMed ID: 15298231
[No Abstract] [Full Text] [Related]
10. How should we support pharmaceutical innovation?
Grootendorst P
Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):313-20. PubMed ID: 19670991
[TBL] [Abstract][Full Text] [Related]
11. Australian pharmaceutical policy: price control, equity, and drug innovation in Australia.
Doran E; Alexander Henry D
J Public Health Policy; 2008 Apr; 29(1):106-20. PubMed ID: 18368023
[TBL] [Abstract][Full Text] [Related]
12. The non-profit sector and the market: opportunities & challenges.
Fund Raising Manage; 2001 Nov; 32(9):42, 46-8. PubMed ID: 11881451
[TBL] [Abstract][Full Text] [Related]
13. Promoting drug discovery by collaborative innovation: a novel risk- and reward-sharing partnership between the German Cancer Research Center and Bayer HealthCare.
Wellenreuther R; Keppler D; Mumberg D; Ziegelbauer K; Lessl M
Drug Discov Today; 2012 Nov; 17(21-22):1242-8. PubMed ID: 22521665
[TBL] [Abstract][Full Text] [Related]
14. Antibiotics at the crossroads.
Nathan C
Nature; 2004 Oct; 431(7011):899-902. PubMed ID: 15496893
[No Abstract] [Full Text] [Related]
15. New non-profit organization will support research to combat neglected diseases.
Walgate R
Bull World Health Organ; 2002; 80(10):842-3. PubMed ID: 12471410
[No Abstract] [Full Text] [Related]
16. Philanthropy's new agenda: creating value.
Porter ME; Kramer MR
Harv Bus Rev; 1999; 77(6):121-30, 216. PubMed ID: 10662001
[TBL] [Abstract][Full Text] [Related]
17. Garry Neil. Interview by Asher Mullard.
Neil G
Nat Rev Drug Discov; 2012 Nov; 11(11):826. PubMed ID: 23123934
[No Abstract] [Full Text] [Related]
18. Funding alert: wake up and support WORLD.
James JS
AIDS Treat News; 2003 May; (391):6-7. PubMed ID: 12866498
[TBL] [Abstract][Full Text] [Related]
19. A decade of fragment-based drug design: strategic advances and lessons learned.
Hajduk PJ; Greer J
Nat Rev Drug Discov; 2007 Mar; 6(3):211-9. PubMed ID: 17290284
[TBL] [Abstract][Full Text] [Related]
20. Model-based drug development survey finds pharmacometrics impacting decision making in the pharmaceutical industry.
Stone JA; Banfield C; Pfister M; Tannenbaum S; Allerheiligen S; Wetherington JD; Krishna R; Grasela DM
J Clin Pharmacol; 2010 Sep; 50(9 Suppl):20S-30S. PubMed ID: 20881214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
